FSD Pharma Inc Class B — Company Overview, News & Financial Data
FSD Pharma Inc. Class B develops innovative therapies for inflammatory diseases, focusing on multiple sclerosis treatment.
FSD Pharma Inc Class B
Company profile
About FSD Pharma Inc Class B
FSD Pharma Inc. Class B (NASDAQ:HUGE) is focused on developing innovative therapies for the treatment of inflammatory diseases. The company is involved in cutting-edge pharmaceutical research, aiming to bring efficient and cost-effective drugs to market. One of its primary projects is Lucid-MS, a treatment for multiple sclerosis. FSD's goal is to leverage its research capabilities and pharmaceutical expertise to address unmet medical needs and improve patient outcomes.
Snapshot
2008Year founded
0Employees
Toronto, CanadaHead office
Loading Map...
Global footprint
Operations
All Locations
Toronto, CA
Products and/or services of FSD Pharma Inc Class B
- Phase 2 clinical trial of FSD201 for the treatment of COVID-19, aimed at addressing inflammatory disorders.
- Psychedelics R&D aimed at exploring novel treatments for mental health disorders, including depression and PTSD.
- Cannabinoid-based pharmaceuticals research focusing on innovative treatments for pain management and other inflammatory conditions.
- Strategic collaboration with other biotech firms to co-develop groundbreaking therapies for various diseases.
- Acquisition and investment in biotech companies to expand research and development capabilities.
- Development of ultramicro PEA molecules targeting chronic inflammatory diseases, promoting advanced therapeutic solutions.
FSD Pharma Inc Class B executive team
- Mr. Zeeshan SaeedFounder, CEO, President & Executive Co-Chairman
- Mr. Anthony John DurkaczFounder & Executive Co-Chairman
- Mr. Nathan Coyle CPAChief Financial Officer
- Mr. Donal Carroll CPAChief Operating Officer
- Dr. Lakshmi P. Kotra BPHARM, Ph.D.CEO of Lucid & Director
- Ms. Maryann AdessoCorporate Secretary
- Randell MackPresident of FSD BioSciences
- Dr. Andrzej Chruscinski M.D., Ph.D.Vice President of Clinical & Scientific Affairs of Lucid
- Mr. Kevin CassidyVice President of Quality-Lucid
GET YOUR GRAFA EDGE NOW
Sign up free to follow this company
We'll switch on a 30-day Edge trial as a welcome gift